DURECT Completes Pharmaceutical Manufacturing Plant

May 24, 2001 — CUPERTINO, CA — Pharmaceutical maker DURECT Corporation has finished construction of a new 8,000 square foot facility that will be used to manufacture DUROS sufentanil.

The facility houses aseptic cleanroom space for aseptic filling and a manufacturing process capable of supporting clean assembly, packaging and labeling. Phase III clinical batches and FDA registration batches of the DUROS drug will be manufactured at the plant.

“We are pleased to reach this important milestone. Construction of this facility was completed on schedule, and we are proceeding with validating and qualifying this facility,” said Jim Brown, CEO of DURECT.

DUROS sufentanil, and FDA approved opiodm is designed to deliver sufentanil on continuous basis for three months for the treatment of chronic pain, which is associated with chronic diseases, including cancer and a number of neurological and skeletal disorders.

POST A COMMENT

Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.